Emerging drugs for autonomic dysfunction in Parkinson's disease

Autores
Pérez Lloret, Santiago; Rey, María Verónica; Pavy Le Traon, Anne; Rascol, Olivier
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments.
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Université Paul Sabatier; Francia
Fil: Rey, María Verónica. Université Paul Sabatier; Francia
Fil: Pavy Le Traon, Anne. Université Paul Sabatier; Francia
Fil: Rascol, Olivier. Université Paul Sabatier; Francia
Materia
Probiotics
Parkinson'S Disease
Drugs
Efficacy And Safety
Botulinum Toxin
Clinical Trials Design
Constipation
Domperidone
Droxidopa
Erectike Dysfunction
Fipamezole
Fludrocortisone
Sexual Dysfunction
Urinary Dysfunction
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/23896
Acceder
id CONICETDig_11d6166a60ef9dd3b438433fc2dffb55
oai_identifier_str oai:ri.conicet.gov.ar:11336/23896
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Emerging drugs for autonomic dysfunction in Parkinson's diseasePérez Lloret, SantiagoRey, María VerónicaPavy Le Traon, AnneRascol, OlivierProbioticsParkinson'S DiseaseDrugsEfficacy And SafetyBotulinum ToxinClinical Trials DesignConstipationDomperidoneDroxidopaErectike DysfunctionFipamezoleFludrocortisoneSexual DysfunctionUrinary Dysfunctionhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments.Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Université Paul Sabatier; FranciaFil: Rey, María Verónica. Université Paul Sabatier; FranciaFil: Pavy Le Traon, Anne. Université Paul Sabatier; FranciaFil: Rascol, Olivier. Université Paul Sabatier; FranciaTaylor & Francis2013-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/23896Pérez Lloret, Santiago; Rey, María Verónica; Pavy Le Traon, Anne; Rascol, Olivier; Emerging drugs for autonomic dysfunction in Parkinson's disease; Taylor & Francis; Expert Opinion on Emerging Drugs; 18; 1; 3-2013; 39-531472-8214CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/abs/10.1517/14728214.2013.766168info:eu-repo/semantics/altIdentifier/doi/10.1517/14728214.2013.766168info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:08:27Zoai:ri.conicet.gov.ar:11336/23896instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:08:27.404CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Emerging drugs for autonomic dysfunction in Parkinson's disease
title Emerging drugs for autonomic dysfunction in Parkinson's disease
spellingShingle Emerging drugs for autonomic dysfunction in Parkinson's disease
Pérez Lloret, Santiago
Probiotics
Parkinson'S Disease
Drugs
Efficacy And Safety
Botulinum Toxin
Clinical Trials Design
Constipation
Domperidone
Droxidopa
Erectike Dysfunction
Fipamezole
Fludrocortisone
Sexual Dysfunction
Urinary Dysfunction
title_short Emerging drugs for autonomic dysfunction in Parkinson's disease
title_full Emerging drugs for autonomic dysfunction in Parkinson's disease
title_fullStr Emerging drugs for autonomic dysfunction in Parkinson's disease
title_full_unstemmed Emerging drugs for autonomic dysfunction in Parkinson's disease
title_sort Emerging drugs for autonomic dysfunction in Parkinson's disease
dc.creator.none.fl_str_mv Pérez Lloret, Santiago
Rey, María Verónica
Pavy Le Traon, Anne
Rascol, Olivier
author Pérez Lloret, Santiago
author_facet Pérez Lloret, Santiago
Rey, María Verónica
Pavy Le Traon, Anne
Rascol, Olivier
author_role author
author2 Rey, María Verónica
Pavy Le Traon, Anne
Rascol, Olivier
author2_role author
author
author
dc.subject.none.fl_str_mv Probiotics
Parkinson'S Disease
Drugs
Efficacy And Safety
Botulinum Toxin
Clinical Trials Design
Constipation
Domperidone
Droxidopa
Erectike Dysfunction
Fipamezole
Fludrocortisone
Sexual Dysfunction
Urinary Dysfunction
topic Probiotics
Parkinson'S Disease
Drugs
Efficacy And Safety
Botulinum Toxin
Clinical Trials Design
Constipation
Domperidone
Droxidopa
Erectike Dysfunction
Fipamezole
Fludrocortisone
Sexual Dysfunction
Urinary Dysfunction
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments.
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Université Paul Sabatier; Francia
Fil: Rey, María Verónica. Université Paul Sabatier; Francia
Fil: Pavy Le Traon, Anne. Université Paul Sabatier; Francia
Fil: Rascol, Olivier. Université Paul Sabatier; Francia
description Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments.
publishDate 2013
dc.date.none.fl_str_mv 2013-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/23896
Pérez Lloret, Santiago; Rey, María Verónica; Pavy Le Traon, Anne; Rascol, Olivier; Emerging drugs for autonomic dysfunction in Parkinson's disease; Taylor & Francis; Expert Opinion on Emerging Drugs; 18; 1; 3-2013; 39-53
1472-8214
CONICET Digital
CONICET
url http://hdl.handle.net/11336/23896
identifier_str_mv Pérez Lloret, Santiago; Rey, María Verónica; Pavy Le Traon, Anne; Rascol, Olivier; Emerging drugs for autonomic dysfunction in Parkinson's disease; Taylor & Francis; Expert Opinion on Emerging Drugs; 18; 1; 3-2013; 39-53
1472-8214
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/abs/10.1517/14728214.2013.766168
info:eu-repo/semantics/altIdentifier/doi/10.1517/14728214.2013.766168
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270045420388352
score 13.13397

Publicaciones similares